JP2011506436A - 細胞傷害性ｔリンパ球抗原４（ｃｔｌａ４）に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法 - Google Patents
細胞傷害性ｔリンパ球抗原４（ｃｔｌａ４）に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法 Download PDFInfo
- Publication number
- JP2011506436A JP2011506436A JP2010537941A JP2010537941A JP2011506436A JP 2011506436 A JP2011506436 A JP 2011506436A JP 2010537941 A JP2010537941 A JP 2010537941A JP 2010537941 A JP2010537941 A JP 2010537941A JP 2011506436 A JP2011506436 A JP 2011506436A
- Authority
- JP
- Japan
- Prior art keywords
- day
- dosage
- days
- administered
- ctla4
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108010021064 CTLA-4 Antigen Proteins 0.000 title claims abstract description 39
- 201000001441 melanoma Diseases 0.000 title claims abstract description 35
- 108010046075 Thymosin Proteins 0.000 title claims abstract description 24
- 102000008203 CTLA-4 Antigen Human genes 0.000 title claims abstract description 15
- 238000000034 method Methods 0.000 title claims description 26
- 238000011282 treatment Methods 0.000 title claims description 25
- 238000011269 treatment regimen Methods 0.000 claims abstract description 12
- 206010027476 Metastases Diseases 0.000 claims abstract description 7
- 238000002648 combination therapy Methods 0.000 claims abstract description 6
- 108010078233 Thymalfasin Proteins 0.000 claims description 46
- 102400000800 Thymosin alpha-1 Human genes 0.000 claims description 46
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 claims description 46
- 229960004231 thymalfasin Drugs 0.000 claims description 46
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims description 16
- 229960005386 ipilimumab Drugs 0.000 claims description 12
- 239000002246 antineoplastic agent Substances 0.000 claims description 6
- 229940034982 antineoplastic agent Drugs 0.000 claims description 5
- 230000037396 body weight Effects 0.000 claims description 5
- 230000009401 metastasis Effects 0.000 claims description 4
- 229960003901 dacarbazine Drugs 0.000 claims description 3
- 239000002295 alkylating antineoplastic agent Substances 0.000 claims 2
- 102000013816 Cytotoxic T-lymphocyte antigen 4 Human genes 0.000 description 24
- 206010028980 Neoplasm Diseases 0.000 description 23
- 239000003814 drug Substances 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 6
- 150000001413 amino acids Chemical group 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 208000000453 Skin Neoplasms Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 201000000849 skin cancer Diseases 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000036765 blood level Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 108700016958 thymosin fraction 5 Proteins 0.000 description 2
- 206010003497 Asphyxia Diseases 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 208000013641 Cerebrofacial arteriovenous metameric syndrome Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000007501 Thymosin Human genes 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1310107P | 2007-12-12 | 2007-12-12 | |
| PCT/US2008/013480 WO2009075813A1 (en) | 2007-12-12 | 2008-12-08 | Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic t lymphocyte-associated antigen 4 (ctla4) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011506436A true JP2011506436A (ja) | 2011-03-03 |
| JP2011506436A5 JP2011506436A5 (enExample) | 2012-01-26 |
Family
ID=40755783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010537941A Withdrawn JP2011506436A (ja) | 2007-12-12 | 2008-12-08 | 細胞傷害性ｔリンパ球抗原４（ｃｔｌａ４）に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20100330093A1 (enExample) |
| EP (1) | EP2240195A4 (enExample) |
| JP (1) | JP2011506436A (enExample) |
| CN (1) | CN101896190A (enExample) |
| AR (1) | AR069682A1 (enExample) |
| AU (1) | AU2008335840A1 (enExample) |
| CA (1) | CA2709027A1 (enExample) |
| WO (1) | WO2009075813A1 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016133059A1 (ja) * | 2015-02-16 | 2016-08-25 | 株式会社ファーマフーズ | Ｆｓｔｌ１を利用した抗がん剤・転移抑制剤およびその併用剤 |
| JP2018501192A (ja) * | 2014-10-21 | 2018-01-18 | サイクロン ファーマシューティカルズ， インク．Ｓｃｉｃｌｏｎｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 免疫刺激剤による癌治療 |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130296223A1 (en) * | 2012-03-30 | 2013-11-07 | Sciclone Pharmaceuticals, Inc. | Use of thymosin alpha for the treatment of sepsis |
| WO2013177102A2 (en) * | 2012-05-21 | 2013-11-28 | Felder Mitchell S | Treatment of cancer by manipulating the immune system |
| JP7069032B2 (ja) | 2016-03-24 | 2022-05-17 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | がん免疫治療における胃腸の免疫関連有害事象の治療方法 |
| TW201735949A (zh) | 2016-03-24 | 2017-10-16 | 千禧製藥公司 | 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法 |
| CN109793891A (zh) * | 2017-11-17 | 2019-05-24 | 韩震 | 多肽化合物在制备提高治疗性抗体疗效的佐剂中的应用与组合物及其制备方法 |
| IT201900016310A1 (it) * | 2019-09-13 | 2021-03-13 | Luigina Romani | Timosina alfa 1 per l’uso nella prevenzione e nel trattamento degli effetti avversi immunitari correlati agli inibitori di checkpoint immunitari. |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2604845A1 (de) * | 1976-02-07 | 1977-08-18 | Knoll Ag | Neue piperazinderivate |
| EP2633866A3 (en) * | 2003-10-17 | 2013-12-18 | Novo Nordisk A/S | Combination therapy |
-
2008
- 2008-12-08 JP JP2010537941A patent/JP2011506436A/ja not_active Withdrawn
- 2008-12-08 AU AU2008335840A patent/AU2008335840A1/en not_active Abandoned
- 2008-12-08 WO PCT/US2008/013480 patent/WO2009075813A1/en not_active Ceased
- 2008-12-08 CA CA2709027A patent/CA2709027A1/en not_active Abandoned
- 2008-12-08 US US12/747,817 patent/US20100330093A1/en not_active Abandoned
- 2008-12-08 CN CN2008801206945A patent/CN101896190A/zh active Pending
- 2008-12-08 EP EP08859253A patent/EP2240195A4/en not_active Withdrawn
- 2008-12-12 AR ARP080105419A patent/AR069682A1/es not_active Application Discontinuation
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018501192A (ja) * | 2014-10-21 | 2018-01-18 | サイクロン ファーマシューティカルズ， インク．Ｓｃｉｃｌｏｎｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 免疫刺激剤による癌治療 |
| JP2021088557A (ja) * | 2014-10-21 | 2021-06-10 | サイクロン ファーマシューティカルズ インターナショナル エルティーディー．Ｓｃｉｃｌｏｎｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｔｄ． | 免疫刺激剤による癌治療 |
| JP7175334B2 (ja) | 2014-10-21 | 2022-11-18 | サイクロン ファーマシューティカルズ インターナショナル エルティーディー． | 免疫刺激剤による癌治療 |
| WO2016133059A1 (ja) * | 2015-02-16 | 2016-08-25 | 株式会社ファーマフーズ | Ｆｓｔｌ１を利用した抗がん剤・転移抑制剤およびその併用剤 |
| US10806787B2 (en) | 2015-02-16 | 2020-10-20 | Pharma Foods International Co., Ltd. | Anticancer agents or antimetastatic agents using FSTL1 and combination drug thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| US20100330093A1 (en) | 2010-12-30 |
| CA2709027A1 (en) | 2009-06-18 |
| WO2009075813A1 (en) | 2009-06-18 |
| EP2240195A1 (en) | 2010-10-20 |
| CN101896190A (zh) | 2010-11-24 |
| EP2240195A4 (en) | 2011-12-21 |
| AU2008335840A1 (en) | 2009-06-18 |
| AR069682A1 (es) | 2010-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023524530A (ja) | 免疫原性が低い癌の癌細胞死滅を増強するための３剤併用療法 | |
| JP2011506436A (ja) | 細胞傷害性ｔリンパ球抗原４（ｃｔｌａ４）に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法 | |
| JP2009542623A (ja) | Ｈ２遮断薬、少なくとも１つの抗炎症薬剤および細胞毒性薬剤を含む抗がん治療 | |
| US20230190733A1 (en) | Methods and compositions for treating cancer | |
| JP2024513505A (ja) | 腫瘍を治療するための組成物及び方法 | |
| US20210379143A1 (en) | Drug containing recombinant mistletoe lectins for treating | |
| US8569280B2 (en) | Methods for the treatment of multiple myeloma | |
| US20060035825A1 (en) | Alpha 5 beta 1 and its ability to regulate the cell survival pathway | |
| JP2011506467A (ja) | 抗悪性腫瘍性熱ショックアポトーシス活性化因子（ｈｓａａ）と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法 | |
| JP6782932B2 (ja) | Ｎｐｒ−ａアゴニストの新規用途 | |
| US20230121867A1 (en) | Compositions and methods for treating diseases and conditions by depletion of mitochondrial or genomic dna from circulation | |
| US8133491B1 (en) | Compositions and methods for treatment of hyperplastic disorders | |
| AU2024208037B2 (en) | Medicinal products and methods for the alleviation of cancer immunotherapy-associated cytokine release syndrome | |
| EP4084820A1 (en) | Fusion proteins and methods of use thereof | |
| US20200093789A1 (en) | Cancer Treatment with a CXCL12 Signaling Inhibitor and an Immune Checkpoint Inhibitor | |
| US11497793B2 (en) | Compositions and methods for treating glioblastoma | |
| JP7317343B2 (ja) | 乳がんの予防又は治療剤及び乳がん細胞の増殖抑制剤 | |
| JP2020524167A (ja) | Ｎｋ−９２細胞とｉｌ−１５アゴニストの併用療法 | |
| US20220409611A1 (en) | Methods of treating, ameliorating, and/or preventing cancer using pyrvinium compositions | |
| WO2025160930A1 (zh) | 母帕司汀(Muparfostat)治疗胰腺癌的用途 | |
| CN120826242A (zh) | 抗cd20抗体药物偶联物在制备治疗套细胞淋巴瘤的药物中的用途 | |
| WO2024145637A2 (en) | Immunotoxin-based targeted therapy for cancer | |
| EP0692259A2 (en) | Use of HCG-specific antibody for the treatment of brain neoplasms | |
| JP2022551672A (ja) | 乳癌治療法 | |
| CN116745619A (zh) | 靶向pacs1的化合物及其使用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111201 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20111201 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20130520 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20130520 |